脓毒症诱导低血压的早期限制性或宽松性液体管理
本研究为在美国60个中心开展的非盲优效性试验,纳入初始1~3升静脉液体复苏后仍存在脓毒症诱导低血压的患者,随机分为限制性液体策略(优先使用升压药、较低静脉液体量)或宽松性液体策略(优先较高静脉液体量后再用升压药),干预24小时。共纳入1563例,限制性液体组782例,宽松性液体组781例。主要终点90天出院前全因死亡在限制性液体组为14.0%,宽松性液体组为14.9%(估计差值-0.9个百分点,95%CI -4.4~2.6,P=0.61),两组严重不良事件报告数相似。结论为限制性液体策略未显著降低(或升高)90天出院前死亡率。
要点
- 脓毒症诱导低血压患者中,限制性液体策略90天出院前全因死亡14.0%(109例),宽松性液体策略14.9%(116例),估计差值-0.9个百分点(95%CI -4.4~2.6,P=0.61)。
- 24小时方案期内,限制性液体组静脉液体量低于宽松性液体组(中位数差值-2134 ml,95%CI -2318~-1949),但升压药使用更早、更普遍、持续时间更长。
- 两组报告严重不良事件数相似。
- 随机化在患者符合脓毒症诱导低血压标准且对初始1~3升静脉液体治疗无效后4小时内进行。
- 该试验为非盲优效性设计,在60个美国中心开展,共纳入1563例患者。
适用人群与场景
- 脓毒症诱导低血压患者,且对初始1~3升静脉液体治疗无效,随机化在符合标准后4小时内进行。
诊断标准与关键阈值
- 脓毒症诱导低血压,且对初始1~3升静脉液体治疗无效。
处置流程与药物剂量
- 限制性液体策略:优先使用升压药并控制较低静脉液体量,持续24小时。
- 宽松性液体策略:优先给予较高静脉液体量,之后使用升压药,持续24小时。
研究设计与关键结果
- 研究类型:非盲优效性试验,美国60个中心,共纳入1563例患者,限制性液体组782例,宽松性液体组781例。
- 主要终点(90天出院前全因死亡):限制性液体组109例(14.0%),宽松性液体组116例(14.9%),估计差值-0.9个百分点(95%CI -4.4~2.6,P=0.61);限制性液体组5例、宽松性液体组4例数据删失(失访)。
- 24小时方案期内静脉液体量:限制性液体组低于宽松性液体组,中位数差值-2134 ml(95%CI -2318~-1949)。
- 升压药使用:限制性液体组更早、更普遍、持续时间更长。
- 安全性:两组报告严重不良事件数相似。
证据类型、等级与局限
- 证据类型:非盲优效性随机对照试验;资助方:美国国家心肺血液研究所;试验注册号:CLOVERS,NCT03434028。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于脓毒症诱导低血压且对初始1~3升静脉液体无效的患者,限制性液体策略(优先升压药)与宽松性液体策略(优先液体)在90天出院前死亡率上无显著差异;原文结论未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Intravenous fluids and vasopressor agents are commonly used in early resuscitation of patients with sepsis, but comparative data for prioritizing their delivery are limited.
METHODS: In an unblinded superiority trial conducted at 60 U.S. centers, we randomly assigned patients to either a restrictive fluid strategy (prioritizing vasopressors and lower intravenous fluid volumes) or a liberal fluid strategy (prioritizing higher volumes of intravenous fluids before vasopressor use) for a 24-hour period. Randomization occurred within 4 hours after a patient met the criteria for sepsis-induced hypotension refractory to initial treatment with 1 to 3 liters of intravenous fluid. We hypothesized that all-cause mortality before discharge home by day 90 (primary outcome) would be lower with a restrictive fluid strategy than with a liberal fluid strategy. Safety was also assessed.
RESULTS: A total of 1563 patients were enrolled, with 782 assigned to the restrictive fluid group and 781 to the liberal fluid group. Resuscitation therapies that were administered during the 24-hour protocol period differed between the two groups; less intravenous fluid was administered in the restrictive fluid group than in the liberal fluid group (difference of medians, -2134 ml; 95% confidence interval [CI], -2318 to -1949), whereas the restrictive fluid group had earlier, more prevalent, and longer duration of vasopressor use. Death from any cause before discharge home by day 90 occurred in 109 patients (14.0%) in the restrictive fluid group and in 116 patients (14.9%) in the liberal fluid group (estimated difference, -0.9 percentage points; 95% CI, -4.4 to 2.6; P = 0.61); 5 patients in the restrictive fluid group and 4 patients in the liberal fluid group had their data censored (lost to follow-up). The number of reported serious adverse events was similar in the two groups.
CONCLUSIONS: Among patients with sepsis-induced hypotension, the restrictive fluid strategy that was used in this trial did not result in significantly lower (or higher) mortality before discharge home by day 90 than the liberal fluid strategy. (Funded by the National Heart, Lung, and Blood Institute; CLOVERS ClinicalTrials.gov number, NCT03434028.).
参考来源
- Shapiro NI, Douglas IS, Brower RG, et al. Early Restrictive or Liberal Fluid Management for Sepsis-Induced Hypotension. N Engl J Med. 2023. PMID: 36688507. doi:10.1056/NEJMoa2212663
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。